About Us
Filament Health is a leading exclusively natural psychedelic drug development company.
We are building a powerful platform to support the treatment of mental health conditions through FDA-approved psychedelic extracts from lab grown and regeneratively harvested plants, produced by our wholly-owned subsidiary, Psilo Scientific.
Company Highlights
Management Team
Deep experience in botanical extraction, intellectual property, biotech, pharma, commercialization and capital markets.
Global Experts in Botanical Extraction and Commercialization
Scaled Mazza Innovation from pre-seed to $26M sale to Sensient Technologies in 2018
Developed and commercialized patent-protected, botanical extraction technology at commercial-scale 35,000 sq. ft. GMP facility
Experienced in audit, accounting, capital markets, M&A and equity financing
Previously cannabis-focused investment banker, Cormark Securities, advising on 75+ financing raising > C$6B in proceeds
Wealth of Relevant Experience in Drug Development, FDA Trials and Intellectual Property
30 years of drug development experience leading regulatory development efforts from pre-IND to post-approval
Extensive global clinical trial application filings and health authority interactions
Extensive patent and trademark portfolio experience in healthcare, technology and other diversified industries
100% pending application to issued patent success rate at Moj.io, Bionic Power & Nextleaf Solutions
Board of Directors and Advisors
Former Managing Director, Head Global Equities, RBC Capital Markets
Chairman, Sundial Growers Inc.
NEO Exchange, Independent Board member
Certified Public Accountant
Previously EVP, Chief Administrative Officer and Chief Financial Officer at Scholastic
Currently Chairman of Acacia Research and board member of ISACA
Partner at Fasken.
Corporate and commercial lawyer specializing in companies in the technology and health sciences sectors including venture capitalists and start-ups
Over 25 years of experience in the life sciences industry most recently as CEO and Director of both private and public companies.
Led Prozac and Zyprexa teams at Eli Lilly.
Founder and VP at Aspreva Pharmaceuticals
Josh Woolley, MD/PhD.
BSc Biology & Psychology, PhD Neuroscience, M.D.
Associate Professor in the Department of Psychiatry and Behavioral Sciences at UCSF; PI and Director of UCSF’s Bonding and Attunement in Neuropsychiatric Disorders Laboratory which is conducting studies on psilocybin and MDMA’s effects on patients with mental illnesses
Communications
Research Partners
Filament has partnered with UCSF’s Translational Psychedelic Research (TrPR) Program to begin two investigator initiated FDA clinical trials in 2021, led by the Program’s Director, Dr. Joshua Woolley.
As a Board Certified Psychiatrist and experienced psychedelics clinician and researcher, Dr. Woolley will act as Principal Investigator in leading Filament’s unique, protected drug candidates through Phase I and Phase II trials.
The TrPR Program combines innovative basic and clinical research approaches to answer key questions about the mechanisms, safety, and efficacy of psychedelics for specific health conditions. The group’s goal is to accelerate progress towards impactful and accessible psychedelic treatments.
UCSF has a history of working in the translational space, linking laboratory science with patients, and findings with the needs of the community. TrPR is committed to building a collaborative culture and applying open science principles to maximize the integrity and transparency of their work.